Pioglitazone: A valuable component of combination therapy for type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1457-1461

  Papanas, Nikolaos ^a   Katsiki, Niki ^b,c   Hatzitolios, Apostolos I ^c   Maltezos, Efstratios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

diabetes mellitus; oral hypoglycemic agents; pioglitazone; thiazolidinediones

Indexed keywords

ALBUMIN; ALEGLITAZAR; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FENOFIBRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; URIC ACID;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CELL FUNCTION; DIABETIC NEUROPATHY; DIABETIC PATIENT; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PLEIOTROPY; REVIEW; WATER RETENTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; THIAZOLIDINEDIONES;

EID: 79958702916     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.568477     Document Type: Review

References (46)

1. Yang W, Lu J, Weng J, et al. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
2. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-6 (Pubitemid 46024990)
3. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
4. Forst T, Hanefeld M, Pfutzner A. Review of approved pioglitazone combinations for type 2 diabetes. Expert Opin Pharamacother 2011;12(10):1571-84
5. Charbonnel BH, Matthews DR, Schernthaner G, et al. QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405 (Pubitemid 40516237)
6. Perriello G, Pampanelli S, Di Pietro C, et al. Italian Pioglitazone Study Group. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabet Med 2006;23:246-52
7. Tan M, Johns D, Gonzalez Galvez G, et al. GLAD Study Group. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004;26:680-93 (Pubitemid 38736958)
8. Tan MH, Baksi A, Krahulec B, et al. GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005;28:544-50 (Pubitemid 40315311)
9. Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
10. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-108 (Pubitemid 351721748)
11. Katsiki N, Georgiadou E, Hatzitolios AI. The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Drugs 2009;69:1417-31
12. Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des 2009;15:3179-92
13. Zhao Y, He X, Huang C, et al. The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis. Diabetes Res Clin Pract 2010;90:279-87
14. Gonzalez-Ortiz M, Hernandez-Salazar E, Kam-Ramos AM, Martinez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract 2007;75:115-18 (Pubitemid 44873140)
15. Derosa G, Cicero AF, Dangelo A, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28:679-88 (Pubitemid 44067262)
16. Derosa G, Dangelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83 (Pubitemid 44060202)
17. Karamanos B, Thanopoulou A, Drossinos V, et al. Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA). Curr Med Res Opin 2011;27:303-13
18. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des 2010;16:3401-16
19. Yamagishi S, Ogasawara S, Mizukami H, et al. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gammaligand, in insulin-deficient diabetic rats. J Neurochem 2008;104:491-9 (Pubitemid 350293884)
20. Maeda T, Kiguchi N, Kobayashi Y, et al. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008;108:341-7
21. Sarafidis PA, Stafylas PC, Georgianos PI, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010;55:835-47
22. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009;8:15-32
23. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003;9:406-16
24. Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010;8:178-84
25. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95 (Pubitemid 47403105)
26. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71 (Pubitemid 46919772)
27. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 28 Jun 2010 [Epub ahead of print].
28. Gale EA. Therapy: the second time as farce: rosiglitazone and the regulators. Nat Rev Endocrinol 2011;7:5-6
29. Doggrell SA. Clinical trials with thiazolidinediones in subjects with type 2 diabetes - is pioglitazone any different from rosiglitazone? Expert Opin Pharmacother 2008;9:405-20 (Pubitemid 351291785)
30. Wilcox R, Bousser MG, Betteridge DJ, et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (prospective pioglitazone clinical trial in macrovascular events 04). Stroke 2007;38:865-73 (Pubitemid 46568445)
31. Erdmann E, Dormandy JA, Charbonnel B, et al.; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80 (Pubitemid 46629127)
32. Erdmann E, Spanheimer R, Charbonnel B, PROactive Study Investigators. Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). J Diabetes 2010;2:212-20
33. Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones - what do meta-analyses really tell us? Diabetes Obes Metab 2010;12:1023-35
34. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89 (Pubitemid 41416583)
35. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8 (Pubitemid 47403104)
36. Nishio K, Kobayashi Y. Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis. Cardiovasc Revasc Med 2010;11:227-31
37. Hong SJ, Kim ST, Kim TJ, et al. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol 2010;30:2655-65
38. Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes. Expert Opin Pharmacother 2008;9:343-9 (Pubitemid 351291781)
39. Ahmed I, Furlong K, Flood J, et al. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Am J Ther 2007;14:49-62 (Pubitemid 46278670)
40. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 2005;27:1181-95 (Pubitemid 41393913)
41. Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016-23 (Pubitemid 44115238)
42. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374:126-35
43. Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs 2010;10:209-16
44. Kawashima S, Matsuoka TA, Kaneto H, et al. Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice. Biochem Biophys Res Commun 2011;404:534-40
45. Wang AP, Li X, Zheng Y, et al. Thiazolidinediones protect mouse pancreatic beta-cells directly from cytokine-induced cytotoxicity through PPARgamma-dependent mechanisms. Acta Diabetol 10 Dec 2010 [Epub ahead of print] Doi: 10.1007/s00592-010-0239-8.
46. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945-61